Oppenheimer Reiterates Outperform on IDEAYA Biosciences, Maintains $53 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating for IDEAYA Biosciences (NASDAQ:IDYA) and maintained a price target of $53.
October 29, 2024 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reiterated its Outperform rating for IDEAYA Biosciences, maintaining a price target of $53, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $53 price target by Oppenheimer suggests a positive outlook for IDEAYA Biosciences. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100